贝那普利联合厄贝沙坦治疗原发性高血压伴左心室肥厚的临床疗效研究

Clinical Efficacy Of Benazepril Combined with Irbesartan in the Treatment of Essential Hypertension with Left Ventricular Hypertrophy Research

目的:探讨贝那普利联合厄贝沙坦治疗原发性高血压(essential hypertension,EH)伴左心室肥厚(left ventricular hypertrophy,LVH)的临床疗效研究。方法:选择2019年6月—2021年6月我院就诊的EH伴LVH患者116例,按照随机数表法分成观察组和对照组,每组58例。对照组采用厄贝沙坦治疗,观察组在对照组基础上联合贝那普利治疗,比较两组临床效果、血压、心率、心室结构以及N-末端脑钠肽前体(NT-proBNP)、超敏C反应蛋白(hs-CRP)水平变化及不良反应发生情况。结果:观察组总有效率为91.38%,高于对照组的75.86%,差异有统计学意义(P<0.05);观察组DBP、SBP低于对照组,差异有统计学意义(P<0.05),两组心率比较,差异无统计学意义(P>0.05);观察组IVST、LVPWT、LVMI及NT-proBNP、hs-CRP水平低于对照组,差异有统计学意义(P<0.05);治疗期间,两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:贝那普利联合厄贝沙坦治疗EH伴LVH患者具有较高的临床效果,能有效降低患者血压,改善其左心室结构,降低NT-proBNP、hs-CRP水平,且具有一定安全性。

Objective:To investigate the clinical effect of benazepril combined with irbesartan in the treatment of essential hypertension with left ventricular hypertrophy.Methods:A total of 116 patients with EH and LVH treated in the hospital were selected from June 2019 to June 2021.According to random number table method,they were divided into observation group and control group,with 58 cases in each group.The control group was treated with irbesartan,while observation group was treated with benazepril on basis of control group.The clinical effect and changes in blood pressure,heart rate,ventricular structure,levels of N-terminal pro-brain natriuretic peptide(NT-proBNP)and high sensitivity C-reactive protein(hs-CRP),the occurrence of adverse reactions were compared between the two group.Results:The total effective rate of the observation group was 91.38%,which was higher than 75.86%of the control group,the difference was statistically significant(P<0.05).DBP and SBP in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).There was no significant difference in heart rate between the two groups(P>0.05).The levels of IVST,LVPWT,LVMI,NT-proBNP and hs-CRP in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions during treatment between the two groups(P>0.05).Conclusion:Benazepril combined with irbesartan has high clinical effect in the treatment of EH patients with LVH,which can effectively reduce blood pressure,improve left ventricular structure,reduce NT-proBNP and hs-CRP levels,and has certain safety.